6-KYC attributes
Advisory for investor
Investor
Disclosures under Regulation 46 of the LODR
|
Investor Charter
Stock Broker
CDSL Depository Participant
NSDL Depository Participant
|
Investor Complaints
Stock Broker Complaints Data
CDSL Complaints Data
NSDL Complaints Data
Form Center
Feedback
Email
Sub Broker Registration
Contact Us
E-Voting Link
CDSL E-voting
NSDL E-voting
NSDL e-Voting
platform
HOME
ABOUT US
TRENDS
EQUITIES
Price Analysis
Top Gainer and Losers
Live Indices
Value/Volume Toppers
Advances & Declines
Only Buyers/Sellers
Block Deals
Index Constituents
Unusual Volume
Historical Returns
Rising Volume Deliverable Volume Falling Price
Index Movers
Sector Watch
52 Week Highs & Lows
Out/Under Performers
News Analysis
Pre Session Commentary
Mid Session Commentary
End Session Commentary
Quick Review
Market Beat
Stock Alert
Hot Pursuit
Foreign Markets
Economy News
Corporate News
Corporate Results
Other Markets
Corporate Action
Board Meetings
Bonus Issues
Rights Issues
Delisted Shares
Market Turnover
Name Change
Split of Face Value
Other Markets
Indian Stocks listed in US (ADR)
FIIS Investments
MF Investments
Indian Rupee
World Markets
Company Information
Detailed Quotes
Company Snapshot
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Quarterly Results
Key Financial Ratios
Share Holding Pattern
Cash Flow
Historical Volume
Director's Report
Score Board
Mutual Fund Holdings
Company News
Peer Comparison
Technical Chart
Derivative
GetQuotes
Nifty Futures
Top Traded Quantity
Top Value Traded
FII Statistics
Daily Settlement Prices
List of Underlying
Put Call Ratio
Cost of Carry
Position Limit
Roll Over
Implied Volatility
Derivatives News
MUTUAL FUND
MF Scheme
Fund-Profile
Scheme Profile
Daily NAV
Historical-NAV
Fund-Performance
Category-Returns
MF Trends
Dividend-Details
MF Activity
Top 10 Holdings
What In Out
Least Volatile Scheme
Scheme Comparison
Portfolio-Comparison
MF Buzz
MF News
New Fund Offer
Fund Manager Interview
MF Tools
Returns Calculator
SIP Calculator
Rank Calculator
Fund Selector
Knowledge Center
MF Form Download
Tax Implication
MF FAQs
NRI Information
IPO
Forthcoming Issues
Open Issues
Closed Issues
New Issue Monitor
New Listing
Basis Of Allotment
Draft-Prospectus
IPO-News
IPO-Download
DEPOSITORY
INSURANCE
SBI Life
Future General Insurance
Religare Health
United Indian Insurance
Cigna TTK Health Insurance
Insurance Premium Calculator
AP DETAILS
Active
Cancel
A+
A
A-
Skip to main content
Home
About Us
Trends
Equities
Derivatives
Mutual Fund
Ipo
Depository
INSURANCE
SBI Life
Future General Insurance
Religare Health
United Indian Insurance
Cigna TTK Health Insurance
Insurance Premium Calculator
AP DETAILS
Active
Cancel
Indrayani Biotech Ltd consolidated sales up 107.88% on year in Q1FY2026, net profit jumped 808.33%
(22:53, 17 Aug 2026)
Back
Indrayani Biotech Ltd share price crashed 8.91% to Rs 7.16. The Company's net profit surged by 808.33% to Rs 1.09 crore, while revenue from operations gained significantly 107.88% to Rs 72.78 crore in Q1FY26 over Q4FY25. The market capitalization of Other Agricultural Products industry group stocks on BSE stood at Rs 57130.8 crore, rising 6.64%. It has improved by 0.77% over last one week and gained upto 1.52% in last one month while the market capitalization of Indrayani Biotech Ltd has nosedived by 16.56% and 33.03% in the same period respectively. Profit before tax (PBT) of Indrayani Biotech Ltd stood at Rs 0.97 crore in Q1 FY26, tanking 88.34% year-on-year, and nosediving by 792.86% quarter-on-quarter. EBITDA came in at Rs 3 crore, plunging by 138.62% YoY and rallying 67.86% sequentially. Total expenses soared by 110.35% to Rs 69.92 crore in Q1FY26 over Q1FY25. During the quarter, cost of materials consumed stood at Rs 51.38 crore, surging by 96.86% YoY, while employee benefits expense was at Rs 7.49 crore, jumping 134.06% YoY. For the TTM ended FY26, revenue from operations plunged by 21.66% to Rs 130.23 crore, while net profit witnessed a sharp fall of 158.64% to Rs 6.11 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 2080% to Rs 3.13 crore, and PBT tanked by 152.32% to Rs 5.74 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 6.74 crore in FY26, as against Rs 30.35 crore in FY25. Indrayani Biotech Ltd tumbled by 45.79% in last one year, underperforming the benchmark BSE Sensex which has slipped by 3.21% during the same period.